SynthesisAdvances in therapy2026
Transitioning Prostacyclin Pathway Agents to Oral Selexipag in Patients with Pulmonary Arterial Hypertension: A Systematic Literature Review.
Synthesis in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Practical Considerations for Managing Transitions from Parenteral Prostacyclins to Oral Selexipag in Pulmonary Arterial Hypertension.Pulmonary therapy · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOral selexipag is indicated to delay disease progression and reduce risk of pulmonary arterial hypertension (PAH)-related hospitalization, as demonstrated in GRIPHON. There are situations when clinicians or patients may need or want to transition from parenteral, oral, and inhaled prostacyclin pathway agents (PPAs) to oral selexipag. This systematic literature review (SLR) examined published evidence on such transitions in adults.
methodsA SLR was conducted in Medline and Embase for publications from January 01, 2015 to September 25, 2024. Two reviewers independently screened abstracts and full texts; one extracted relevant data.
resultsOverall, 1730 publications were identified, with 48 included. Of these, 32 transitions from treprostinil and 16 from epoprostenol to oral selexipag were identified. Patient ages ranged from 19 to 78 years, with varying risk status and scores, functional classes, and comorbidities. Reasons for transition were patient-specific, with publications generally following GRIPHON and Food and Drug Administration (FDA) label protocols.
conclusionThis review highlights cases where oral selexipag may be a suitable option when clinicians and patients participate in shared decision-making considering safety and risks/benefits. Transitions should be individualized based on clinical assessment, with appropriate monitoring and follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.